Efficacy of Once-Daily Urapidil Treatment in Mild or Moderate Essential Hypertension Assessed by Ambulatory 24-Hour Blood Pressure Monitoring

Trimarcö, Bruno; Rosiello, G.; Feldhaus, P; Steinijans, V W; Vecchione, F.; Cuocolo, Alberto; Lembo, Giuseppe; Volpe, Massimo

doi:10.2165/00003495-198800356-00023

Cited by 4 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Следует также придерживаться рациональных режимов назначения капсульной формы препарата для перорального применения. При таком способе предпочтительным является прием 60 мг 2 раза в сут, так как при однократном приеме 120 мг в сут риск побочных эффектов, в частности, головокружение, общая слабость -оказывался выше [27].…”

Section: переносимость и безопасностьunclassified

Urapidil in the Treatment of Medical Emergencies Caused by Blood Pressure Increase

Гапонова

Абдрахманов

Tereschenko

2012

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Обсуждают результаты экспериментальных и клинических исследований, посвященных препарату урапидил, совмещающему центральный антигипертензивный эффект с периферической вазодилатацией. Отражены области применения, подчеркнута хорошая переносимость и безопасность препарата. Подробно изложены способы применения урапидила при различных клинических ситуациях, сопровождающихся острым повышением артериального давления.

show abstract

Section: переносимость и безопасностьunclassified

Urapidil in the Treatment of Medical Emergencies Caused by Blood Pressure Increase

Гапонова

Абдрахманов

Tereschenko

2012

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

show abstract

Biochemical effects of urapidil on red cell membrane ion transport systems in a population of elderly essential hypertensives

Antonicelli

Balducci

Lipponi

et al. 1991

Postgraduate Medical Journal

View full text Add to dashboard Cite

Summary:The aim of our work was to verify the effect of urapidil on membrane ion transport systems. This was a randomized, double-blind, cross-over study which evaluated the clinical and biochemical effects of urapidil (30 mg twice daily in comparison with placebo) in a group of 10 elderly hypertensive patients (3 male, 7 female ranging from 68 to 90 years, mean age 79.2 ± 7.6 years). For the evaluation in fresh erythrocytes of principal ion transport systems (cotransport Na+/K+, countertransport Na+/Li+, Na+/K+ ATPase pump. intracellular Na' and K+) we used the nystatin technique. We found that urapidil activated the red cell membrane ions cotransport system (basal values: 83.7 ± 50.3 imol Na' RBC 1 -'.h-, after 1 month of urapidil therapy: 181.5 ± 89.3 ILmol Na' RBC 1-'.h-1) (P <0.01), without significant changes in the other biochemical parameters evaluated.Our data suggest that one of the mechanisms of the urapidil antihypertensive effect could involve an increase in the membrane sodium cotransport system.

show abstract

Urapidil

Langtry¹,

Mammen²,

Sorkin³

1989

Drugs

View full text Add to dashboard Cite

Urapidil is a postsynaptic alpha 1-adrenoceptor antagonist with a pharmacodynamic profile similar to prazosin. Unlike prazosin, however, urapidil also has some central activity which may explain the apparent improved tolerability of urapidil, including the absence of first-dose syncope. In clinical trials urapidil therapy resulted in significant reductions in blood pressure in patients with mild to severe essential hypertension, with little influence on heart rate. It is an effective antihypertensive when administered as monotherapy or in combination with beta-blockers and thiazide diuretics. In the few patients with cardiac dysfunction who have been studied to date, urapidil has improved myocardial oxygen consumption, systemic vascular resistance, left ventricular function, cardiac output and pulmonary capillary wedge pressure; however, further study is needed to assess the full therapeutic potential of urapidil in these patients. Urapidil has also been used successfully in the treatment of hypertensive emergencies, including eclampsia and pre-eclampsia, hypertensive crisis and hypertension occurring during general and cardiac surgery, rapidly lowering blood pressure without altering heart rate. Urapidil does not affect lipid or glucose metabolism, nor does it impair renal function. In addition, urapidil may be beneficial to patients with pulmonary hypertension, in whom it dilates pulmonary vascular beds to a greater extent than systemic vasculature, although therapeutic trials have not examined this effect. The most common adverse effects associated with urapidil therapy are dizziness, nausea, headache, fatigue and palpitations; however, these tend to be mild and transient and usually do not require discontinuation of treatment. Thus, urapidil offers a useful alternative to currently available drugs for the treatment of mild to severe hypertension, either as monotherapy or in combination with other antihypertensive drugs.

show abstract

Efficacy of Once-Daily Urapidil Treatment in Mild or Moderate Essential Hypertension Assessed by Ambulatory 24-Hour Blood Pressure Monitoring

Cited by 4 publications

References 1 publication

Urapidil in the Treatment of Medical Emergencies Caused by Blood Pressure Increase

Urapidil in the Treatment of Medical Emergencies Caused by Blood Pressure Increase

Biochemical effects of urapidil on red cell membrane ion transport systems in a population of elderly essential hypertensives

Urapidil

Contact Info

Product

Resources

About